Urogen Pharma (URGN) Receives Average Recommendation of “Buy” from Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $37.67.

Several research analysts recently weighed in on the stock. UBS AG cut shares of Urogen Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Oppenheimer Holdings, Inc. set a $51.00 price objective on shares of Urogen Pharma and gave the stock an “outperform” rating in a research report on Tuesday. Zacks Investment Research cut shares of Urogen Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, September 14th. Finally, Jefferies Group LLC boosted their price objective on shares of Urogen Pharma from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Monday, October 9th.

Several institutional investors have recently modified their holdings of URGN. State of Tennessee Treasury Department bought a new stake in shares of Urogen Pharma during the 3rd quarter valued at $158,000. JPMorgan Chase & Co. bought a new stake in shares of Urogen Pharma during the 3rd quarter valued at $168,000. Alps Advisors Inc. bought a new stake in shares of Urogen Pharma during the 2nd quarter valued at $195,000. Shikiar Asset Management Inc. bought a new stake in shares of Urogen Pharma in the 3rd quarter valued at $665,000. Finally, LLBH Private Wealth Management LLC bought a new stake in shares of Urogen Pharma in the 2nd quarter valued at $695,000. Institutional investors own 40.55% of the company’s stock.

Urogen Pharma (NASDAQ:URGN) traded down $1.08 during mid-day trading on Wednesday, reaching $42.18. 127,100 shares of the company traded hands, compared to its average volume of 59,653. Urogen Pharma has a 1 year low of $13.01 and a 1 year high of $44.63.

TRADEMARK VIOLATION NOTICE: “Urogen Pharma (URGN) Receives Average Recommendation of “Buy” from Analysts” was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.themarketsdaily.com/2017/11/15/urogen-pharma-urgn-receives-average-recommendation-of-buy-from-analysts.html.

Urogen Pharma Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply